EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Adverse outcomes between VMAT2 and anticholinergics in tardive dyskinesia: A target trial emulation

Tien-Wei Hsu iD, Chih-Wei Hsu iD, Ping-Tao Tseng iD, Yi-Ya Fang, Chuo-Yu Lee, Yu-Hsuan Lin, Brendon Stubbs, Trevor Thompson, Andre F Carvalho, Yu-Chen Kao, Jen-Ping Chen iD, Fu-Chi Yang iD und 2 weitere

Psychiatry and Clinical Neurosciences · 2026-08 · 80 (8) · 637-644

DOI: 10.1111/pcn.70056 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Psychiatry and Clinical Neurosciences, online erschienen am 07.04.2026. Verfasst von Tien-Wei Hsu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, E-DA Dachang Hospital, I-Shou University, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Vesicular Monoamine Transport Proteins, Cholinergic Antagonists, Tardive Dyskinesia, Accidental Falls. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Tri-Service General Hospital, Ministry of National Defense Medical Affairs Bureau, National Science and Technology Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Vesicular monoamine transporter 2 (VMAT2) inhibitors have been approved for the treatment of tardive dyskinesia (TD), whereas anticholinergic agents are still widely used for this condition. This study aimed to compare the risk of major clinical adverse outcomes among patients with TD treated with VMAT2 inhibitors versus anticholinergic agents.

Methods

This retrospective cohort study used the TriNetX collaborative network, which aggregates de‐identified electronic health records (EHRs) across the United States. Adults aged≧18 years with TD who initiated anticholinergic agents or VMAT2 inhibitors for the first time between 2019 and 2025 were included. We applied a target trial emulation framework under the intention‐to‐treat principle. 1:1 propensity score matching was applied. Cox hazard regression was used to assess the primary outcomes: incident fall, injury, fracture, and mortality, and secondary outcomes: incident delirium, dementia, and arrythmia.

Results

After propensity score matching, 2749 patients (mean age: 59 years; 34% male) were included in each treatment group with well‐balanced demographics. Compared with anticholinergic therapy, VMAT2 inhibitors were associated with significantly lower risks of fall (HR = 0.83, 95% CI = 0.73–0.93), injury (HR = 0.77, 95% CI = 0.71–0.85), fracture (HR = 0.82, 95 % CI = 0.72–0.94), and mortality (HR = 0.71, 95% CI = 0.58–0.87). Secondary outcomes also favored VMAT2 inhibitors, with reduced risks of delirium (HR = 0.39, 95% CI = 0.29–0.52), dementia (HR = 0.55, 95 % CI = 0.45–0.69), and arrhythmia (HR = 0.72, 95% CI = 0.60–0.85).

Conclusion

This real‐world study suggests that VMAT2 inhibitors may offer a safer therapeutic option than anticholinergic agents for TD management, supporting their potential clinical advantage and the need for further long‐term validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vesicular Monoamine Transport ProteinsCholinergic AntagonistsTardive DyskinesiaAccidental FallsHumansFemaleMiddle AgedMaleRetrospective StudiesAged

Stichwörter der Autor:innen

anticholinergic agentsfallmortalitytardive dyskinesiavesicular monoamine transporter 2 inhibitor

Substanzen

Vesicular Monoamine Transport ProteinsCholinergic AntagonistsSLC18A2 protein, human

Autor:innen und Institutionen

  • Department of Psychiatry, E-DA Dachang Hospital, I-Shou University, Kaohsiung, Taiwan.
  • Department of Psychiatry, E-DA Hospital, I-Shou University, Kaohsiung, Taiwan.
  • School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan.
  • Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
  • Institute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung, Taiwan.
  • Department of Psychology, College of Medical and Health Science, Asia University, Taichung, Taiwan.

ORCID-Profile: Tien-Wei Hsu, Chih-Wei Hsu, Ping-Tao Tseng, Jen-Ping Chen, Fu-Chi Yang, Chia-Kuang Tsai, Chih-Sung Liang

Förderung

  • Tri-Service General Hospital
  • Ministry of National Defense Medical Affairs Bureau
  • National Science and Technology Council

Zitieren

APA

Hsu, T. W., Hsu, C. W., Tseng, P. T., Fang, Y. Y., Lee, C. Y., Lin, Y. H., Stubbs, B., Thompson, T., Carvalho, A. F., Kao, Y. C., Chen, J. P., Yang, F. C., Tsai, C. K., & Liang, C. S. (2026). Adverse outcomes between VMAT2 and anticholinergics in tardive dyskinesia: A target trial emulation. Psychiatry and Clinical Neurosciences, 80(8), 637-644. https://doi.org/10.1111/pcn.70056

Vancouver

Hsu TW, Hsu CW, Tseng PT, Fang YY, Lee CY, Lin YH, et al. Adverse outcomes between VMAT2 and anticholinergics in tardive dyskinesia: A target trial emulation. Psychiatry and Clinical Neurosciences. 2026;80(8):637-644. doi:10.1111/pcn.70056

BibTeX
@article{Hsu2026,
  author = {Hsu, Tien-Wei and Hsu, Chih-Wei and Tseng, Ping-Tao and Fang, Yi-Ya and Lee, Chuo-Yu and Lin, Yu-Hsuan and Stubbs, Brendon and Thompson, Trevor and Carvalho, Andre F and Kao, Yu-Chen and Chen, Jen-Ping and Yang, Fu-Chi and Tsai, Chia-Kuang and Liang, Chih-Sung},
  title = {Adverse outcomes between VMAT2 and anticholinergics in tardive dyskinesia: A target trial emulation},
  journal = {Psychiatry and Clinical Neurosciences},
  year = {2026},
  volume = {80},
  number = {8},
  pages = {637--644},
  doi = {10.1111/pcn.70056}
}
Kostenlos starten →